Verizon Communications Inc. (NYSE:VZ) increased price it charges subscribers to upgrade new device

Verizon Communications Inc. (NYSE:VZ) has increased the price it charges subscribers to upgrade to a new device or add a phone to a new line. AT&T is nudging up the price of its unlimited data plans, which are no longer available but are still held by certain longstanding customers.

Verizon Communications Inc. (NYSE:VZ) traded 11.78 Million shares and was closed at $52.76 per share. The current share price indicates that stock is -4.34% away from its one year high and is moving 25.72% ahead of its one year low. Stock monthly performance is recorded as 4.29% while its performance in last 5 sessions is -2.30%.

Analyst’s Analysis on Verizon Communications Inc. (NYSE:VZ)

At the movement stock is under coverage by number of analysts. 5 given Buy rating to the stock whereas 1 analyst given UNDERPERFORM rating to stock and 17 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.48 on scale of 1-5. Analysts mean target price for Verizon Communications Inc. (NYSE:VZ) is $52.77 while their mean recommendation is 2.50 (1=Buy, 5=sell).

Shopify Inc. (NYSE:SHOP) shares moved to $47.87 after starting the day at $47.02 on Tuesday. Weekly volatility of SHOP is 4.51% and monthly volatility is 3.32%. Stock performance in last five sessions is recorded as 11.79% while year to date (YTD) performance is 11.66%. SHOP Gross Margin is 52.70% and its return on assets is -10.70%. Stock 3 months performance is recorded as 9.47%.

Analyst Rating on Shopify Inc. (NYSE:SHOP)

Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 11 analysts of Thomson Reuters, 7 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for SHOP is $51.35 while analysts mean recommendation is 2.00.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced that the 505(b)(2) New Drug Application (NDA) for its novel pemetrexed drug product has been submitted to the U.S. Food and Drug Administration (FDA).

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) traded 646407 shares and was closed at $66.35 per share. The current share price indicate that stock is -25.00% away from its one year high and is moving 100.94% ahead of its one year low. Stock monthly performance is recorded as -13.35% while its performance in last 5 sessions is -17.18%.

Analyst’s Analysis on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

At the movement stock is under coverage by number of analysts. At the movement stock is under coverage by number of analysts. 1 given Buy rating to the stock whereas 1 analyst given UNDERPERFORM rating to stock and no analyst given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.25 on scale of 1-5. Analysts mean target price for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is $92.75 while their mean recommendation is 2.00 (1=Buy, 5=sell).

NiSource Inc. (NYSE:NI) shares moved to $21.94 after starting the day at $22.05 on Tuesday. Weekly volatility of NI is 1.96% and monthly volatility is 1.63%. Stock performance in last five sessions is recorded as -1.13% while year to date (YTD) performance is -0.90%. NI Gross Margin is 70.00% and its return on assets is 2.40%. Firm quarterly performance is -3.53%.

Analyst Recommendation on NiSource Inc. (NYSE:NI)

Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 9 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating to NiSource Inc. (NYSE:NI) stock. Analyst’s mean target price for NI is $23.81 while analysts mean recommendation is 2.70.

Leave a Reply

Your email address will not be published. Required fields are marked *